Inhalation Sciences (ISAB): 2020 outlook

Report this content

(Stockholm Jan 27, 2020) Inhalation Sciences’ CEO Manoush Masarrat is looking forward to an eventful year ahead for ISAB, with its world-leading in vitro tool DissolvIt reaching full commercialization, new CRO projects, ongoing clinical validation of PreciseInhale, a packed event schedule and new faces joining the lab. “2020 is going to a very busy year” says Masarrat.

After four months as CEO of ISAB and 10 months on its Board, Manoush Masarrat is now firmly behind the wheel. He expects the company to shift up a gear as it accelerates into what he believes could be a pivotal year. “Scientifically, strategically and financially 2020 is going to be important, both for us and our stakeholders”.

2020 Outlook:

  • THE YEAR OF DissolvIt

“In Q1, we plan to launch the DissolvIt module and ship two systems that we’ve already announced to two of our existing customers” says Masarrat “and a third is planned to be shipped in Q2 to a new customer, as part of the 3 MSEK deal we recently announced.”

IVIVC (In Vitro In Vivo Correlation) has long been sought-after by the inhaled pharmaceutical industry, Masarrat points out. “And when it comes to IVIVC, DissolvIt has always been leading. Delivering IVIVC data in the preclinical stage, it enables drug developers to predict how aerosols will behave in human lungs—reducing risk, preventing clinical failure and cutting months if not years off drug development. In Q1 2020 DissolvIt will be up and running in commercial labs generating credible, repeatable IVIVC data. DissolvIt is going to be a major part of our future”.

  • VALIDATION OF PreciseInhale in clinical trials

At the other end of drug development, the validation of PreciseInhale in clinical trials is vital for ISAB’s continuing scientific, and ultimately commercial, leadership. “Validating PreciseInhale for use in clinical as well as preclinical studies again provides the industry with full IVIVC and cements our leading reputation. We know of no other system that can generate precise, predictive, repeatable data end-to-end throughout drug development, from preclinical to clinical testing. Our ambition is to have the validation finalized during 2020 and we see an enormous potential with it.

  • CRO

Masarrat is also announcing that he expects new CRO (Contract Research) assignments from both existing and new customers in 2020. He is keen to underline the importance of CRO to ISAB as one of its three core platforms.

“CRO is crucial” he says “it is in the laboratory where we’ve engineered our most successful customer relationships. The strategic benefits IVIVC and PreciseInhale deliver mean we of course aim to talk to Management Teams and Boardrooms. But we mustn’t ever forget either, that all the painstaking development work we have done on PreciseInhale and DissolvIt was achieved through CRO work we’ve carried out for the very best inhalation companies in the business”.

“Throughout 2020 I want us to remember that ISAB is built on three powerful platforms—and they all play a crucial role. Firstly of course there are our products. Secondly our CRO research services, that both bring new customers in and help us develop our products. And finally, there are the papers and publications that we and our customers publish which prove we produce outstanding, repeatable data that other systems just aren’t able to produce.”


ISAB also expanded its customer base in 2019, Masarrat points out, and expects to do the same in 2020. Hand-in-hand with a growing client base will be the need for more resources in the company’s central facilities just outside Stockholm. “This year we will take on a Product Engineer, a Regulatory and Quality Control Manager plus a part-time Office Manager. The expansion we’re seeing in our customers and markets require growing skillsets”.


“From California to Scotland to Sweden to Germany we’ll be at a broad range of industry events this year” says Masarrat “meeting people, sharing our technology and offerings and reminding everyone of the repeatable, predictive IVIVC data we can help them capture. Watching DissolvIt hit the labs this year, and seeing the data emerge from its rollout is going to be a big moment for us. 2020 is definitely one to watch”.

Watch CEO Manoush Masarrat interviewed HERE.

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided through the agency of the contact person above, for publication on January 27, 2020.



Documents & Links